GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Issuance of Debt

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Issuance of Debt : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Issuance of Debt?

Freeline Therapeutics Holdings's Issuance of Debt for the three months ended in Sep. 2023 was $0.00 Mil.

Freeline Therapeutics Holdings's Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.


Freeline Therapeutics Holdings Issuance of Debt Historical Data

The historical data trend for Freeline Therapeutics Holdings's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Issuance of Debt Chart

Freeline Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Issuance of Debt
- - - - -

Freeline Therapeutics Holdings Quarterly Data
Dec18 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Freeline Therapeutics Holdings Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Freeline Therapeutics Holdings Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.